Searched for
CANMAB
Buy Biocon, target price Rs 390: GeojitAccording to the brokerage, new product launches and smooth operation amidst US FDA approval for most of the facilities should support long...- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...
- HC allows Biocon, Mylan to sell their drug for three cancersBiocon and Mylan had appealed against the single judge order as restrictions were imposed on the use of clinical data in the package insert...
- Delhi HC asks government if it approved Biocon’s trastuzumab for three cancersBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- EMA accepts Biocon and Mylan's regulatory submission for proposed breast cancer biosimilar drugBiocon and Mylan are engaged in a court battle in India against Swiss biotech firm Roche over marketing restrictions imposed on their trast...
- Biosimilar drugs are priced too high and do little to improve accessibility: DoctorsBiosimilar drugs are follow-on biologics that have nearly the same efficacy as the original drug and used to treat cancer or autoimmune dis...
- Reliance Life Sciences appeals marketing restrictions on breast cancer drugThe counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...
- Biotech giant Roche takes NPPA to court over cap on injection priceOn May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
- Biocon, Mylan likely to appeal Delhi HC ruling on Roche's cancer drug trastuzumabThe order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...
- Zydus Cadila launches copy of Roche’s breast cancer drug HerceptinZydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...
- Biocon, Mylan challenge ban on using Roche dataBangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...
- Pricing of our breast cancer drug helped expand market: BioconCanmab is considered a breakthrough in biosimilar drugs and is expected to treat about 35,000 breast cancer patients in the country.
- Investors should not lose hope in Biocon despite weak Q3 showBiocon plunged nearly 6% on Thursday, after its net profit rose 14% to Rs 105 crore for the quarter ended December 31 which was largely in ...
- Ten stocks in focus in Monday morning tradeIndian markets are likely to trade in a range. Here is a list of ten stocks which are likely to be in focus in trade today.
- Biocon launches breast-cancer drug CANMAbPriced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.
- Biocon's breast cancer drug 'CANMAb' to hit markets next monthBiotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next ...
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
Load More
